Clinical Trials
13 trialsNCT04328844 2026-03-30
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Phase 1 Active not recruiting
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT04336241 2026-02-27
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune, Inc.
Phase 1 Active not recruiting
NCT05047536 2025-12-19
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Phase 1 Terminated
NCT04130516 2025-12-18
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Linnaeus Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05812027 2025-11-17
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics, Inc.
Active not recruiting
NCT06805825 2025-09-23
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
Phase 1 Recruiting
NCT04993677 2025-05-11
A Study of SEA-CD40 Given With Other Drugs in Cancers
Seagen Inc.
Phase 2 Completed
NCT05576077 2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1 Terminated
NCT00986661 2022-11-02
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Provectus Pharmaceuticals
Phase 1 Unknown
NCT03297424 2022-07-25
A Study of PLX2853 in Advanced Malignancies.
Opna Bio LLC
Phase 1 Completed
NCT02315066 2022-04-21
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
Phase 1 Completed
NCT03652077 2021-11-15
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed